These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 11257811)
1. [Evaluation of the therapeutic effects in individual patients with Alzheimer disease]. Richard E; Lemstra AW; Walstra GJ; van Gool WA Ned Tijdschr Geneeskd; 2001 Feb; 145(8):340-5. PubMed ID: 11257811 [TBL] [Abstract][Full Text] [Related]
2. [Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy]. Richard E; Walstra GJ; van Campen J; Vissers E; van Gool WA Ned Tijdschr Geneeskd; 2002 Jan; 146(1):24-7. PubMed ID: 11802333 [TBL] [Abstract][Full Text] [Related]
3. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Sano M; Wilcock GK; van Baelen B; Kavanagh S Int J Geriatr Psychiatry; 2003 Oct; 18(10):942-50. PubMed ID: 14533127 [TBL] [Abstract][Full Text] [Related]
4. A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Gauthier S; Juby A; Morelli L; Rehel B; Schecter R; Curr Med Res Opin; 2006 Nov; 22(11):2251-65. PubMed ID: 17076986 [TBL] [Abstract][Full Text] [Related]
5. Do cholinesterase inhibitors slow progression of Alzheimer's disease? Farlow MR Int J Clin Pract Suppl; 2002 Jun; (127):37-44. PubMed ID: 12139366 [TBL] [Abstract][Full Text] [Related]
6. Donepezil treatment of severe Alzheimer's disease in nursing home settings. A responder analysis. Jelic V; Haglund A; Kowalski J; Langworth S; Winblad B Dement Geriatr Cogn Disord; 2008; 26(5):458-66. PubMed ID: 18984956 [TBL] [Abstract][Full Text] [Related]
7. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine]. Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553 [TBL] [Abstract][Full Text] [Related]
8. [Variability of efficacy measures in Alzheimer's disease]. Musicco M; Pettenati C; Caltagirone C Ann Ist Super Sanita; 2005; 41(1):87-91. PubMed ID: 16037656 [TBL] [Abstract][Full Text] [Related]
9. Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study. Rockwood K; Black S; Bedard MA; Tran T; Lussier I; Int J Geriatr Psychiatry; 2007 Apr; 22(4):312-9. PubMed ID: 17006874 [TBL] [Abstract][Full Text] [Related]
10. No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment. Auriacombe S; Pere JJ; Curr Med Res Opin; 2003; 19(8):715-7. PubMed ID: 14687442 [No Abstract] [Full Text] [Related]
11. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
13. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032 [TBL] [Abstract][Full Text] [Related]
14. Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Freund-Levi Y; Basun H; Cederholm T; Faxén-Irving G; Garlind A; Grut M; Vedin I; Palmblad J; Wahlund LO; Eriksdotter-Jönhagen M Int J Geriatr Psychiatry; 2008 Feb; 23(2):161-9. PubMed ID: 17582225 [TBL] [Abstract][Full Text] [Related]
16. Verbal repetition in patients with Alzheimer's disease who receive donepezil. Asp E; Cloutier F; Fay S; Cook C; Robertson ML; Fisk J; Dei DW; Rockwood K Int J Geriatr Psychiatry; 2006 May; 21(5):426-31. PubMed ID: 16676290 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial. Feldman H; Gauthier S; Hecker J; Vellas B; Xu Y; Ieni JR; Schwam EM; Int J Geriatr Psychiatry; 2005 Jun; 20(6):559-69. PubMed ID: 15920715 [TBL] [Abstract][Full Text] [Related]
18. Donepezil in Alzheimer's disease: what to expect after 3 years of treatment in a routine clinical setting. Wallin AK; Andreasen N; Eriksson S; Båtsman S; Nasman B; Ekdahl A; Kilander L; Grut M; Rydén M; Wallin A; Jonsson M; Olofsson H; Londos E; Wattmo C; Eriksdotter Jonhagen M; Minthon L; Dement Geriatr Cogn Disord; 2007; 23(3):150-60. PubMed ID: 17312368 [TBL] [Abstract][Full Text] [Related]
19. Measuring cognitive change in Alzheimer's disease clinical drug trials. Harrison JE J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492 [TBL] [Abstract][Full Text] [Related]
20. [Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko]. Gasser US; Gasser T MMW Fortschr Med; 2001 Dec; 143(51-52):40-1. PubMed ID: 11824165 [No Abstract] [Full Text] [Related] [Next] [New Search]